UBS Group
PARN

UBS Group’s Parnell Pharmaceuticals Holdings Ltd PARN Stock Holding History

UBS Group’s Portfolio PARN Stock Details PARN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-4,023
Closed -$7K – 8407
2016
Q2 		$7K Buy
+4,023
New +$7.39K ﹤0.01% 7022
2016
Q1 		– Sell
-1,071
Closed -$4K – 8903
2015
Q4 		$4K Sell
1,071
-2,598
-71% -$9.88K ﹤0.01% 7849
2015
Q3 		$13K Buy
3,669
+702
+24% +$2.98K ﹤0.01% 7121
2015
Q2 		$15K Buy
+2,967
New +$13.1K ﹤0.01% 7170
2015
Q1 		– Sell
-251
Closed -$1K – 10227
2014
Q4 		$1K Buy
+251
New +$1.14K ﹤0.01% 9651

Other funds holding PARN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

UBS Group's PARN Position: Q3 2016 in Review

UBS Group sold out of Parnell Pharmaceuticals Holdings Ltd (PARN) in Q3 2016, closing a stake of 4,023 shares — an estimated $7K sold.

UBS Group first reported a position in PARN in Q4 2014 and held it in 5 quarters. The position peaked at $15K in Q2 2015. 18 funds tracked by Wall St. Rank hold PARN as of Q3 2016.

  • UBS Group reported no remaining Parnell Pharmaceuticals Holdings Ltd position as of Q3 2016 after selling out during the quarter.
  • UBS Group sold 4,023 Parnell Pharmaceuticals Holdings Ltd shares in Q3 2016, an estimated $7K.
  • UBS Group first reported a position in Parnell Pharmaceuticals Holdings Ltd in Q4 2014 and held it in 5 quarters.
  • UBS Group's Parnell Pharmaceuticals Holdings Ltd position peaked at $15K in Q2 2015.
  • 18 funds tracked by Wall St. Rank held Parnell Pharmaceuticals Holdings Ltd as of Q3 2016.

Based on UBS Group's 13F filing for Q3 2016, filed 14 Nov 2016.